MyHomeGuard is more than just household insurance. It provides cover for ATM assault, injuries resulting from theft, and personal accidents that occur outside your home.
Chubb leverages superior underwriting expertise and world renowned claims, account services, and financial strength to offer solutions for small and medium businesses.
Today’s multinational organizations face complex and interconnected risks. We offer insurance solutions that are tailored to global needs as well as local requirements, helping them address their risk management challenges.
New Trends for the New Generation! Be a CHUBB Slasher!
Our partners’ contributions to our success are undeniable. As one of the world’s largest and strongest insurers, we offer a range of products and services capabilities through our distribution channels to ensure yours, too.
Chubb has a proven track record of maximising ancillary revenue for more than 120 business partners across Asia Pacific.
AEON & Chubb Life join hands to secure your future.
Protect your travel adventures, home, and everyday moments with Chubb’s General Insurance. Enjoy flexible coverage from a global insurance leader and buy online in minutes—peace of mind is just a click away.
Buy life insurance online for all your needs—critical illness, accidents, and term life. Enjoy comprehensive protection, health and wellness benefits, and flexible coverage options with easy online purchase.
As the scientific community races to respond to COVID-19, best practice is slipping in clinical trials. What trade-offs are being made and who is liable?
The urgency of the COVID-19 health crisis has led to a frenzy of clinical trial activity. After the Chinese authorities shared the COVID-19 genome with the international community in January 2020, it took just six weeks for the first candidate vaccine to be shipped for human clinical trials. By early August 2020, close to 3,000 trials were under way around the world, attempting to halt the progress of COVID-19 at different points along the biochemical pathway it takes into the human body. The pace at which these candidates were prepared shows how far both our understanding of the disease has come and the speed with which science can move.
However, with all eyes on the goal of beating COVID-19 fast and the scientific and medical communities throwing everything they have at COVID-19, there are risk implications not only for the researchers running trials, but also for product owners whose drugs are being tested against the disease. While the regulatory environment is allowing for fast-tracked trials and greater leniency, this will not extend to compromised patient safety.
The context may be a very immediate health crisis, but the trade-offs being made are creating long-term risks that someone will be liable for and which must be managed accordingly.
Read the “Emerging Risks in COVID-19 Clinical Trials” report to learn more about the emerging risks and how they can be mitigated.
Key takeaways
- It would be unwise for researchers to give drugs to research subjects who could otherwise be excluded.
- Changes and revisions to primary endpoints should be uncommon.
- Product manufacturers should stay alert to how their products are being used.
- Regulations may have been relaxed but product liability law remains the same.
- Lessons are being learnt about how to structure trials more efficiently and global coordination.
Read more reports in the ‘Life Science in the era of pandemics’ series:
Insights and Expertise
3 key risks facing the life sciences industry
The great telehealth experiment
Making medical devices during a pandemic
3 big questions with life science expert Travis McIntosh
Fighting COVID-19 with genomics
Lessons from the supply chain
No part of this article may be reproduced in any written, electronic, recording, or printed form without written permission of Chubb.
Disclaimer - All contents of this article are intended for general information/guidance purposes only and not intended to be an offer or solicitation of insurance products or personal advice or a recommendation to any individual or business of any product or service. This article should not be relied on for legal advice or policy coverage and cannot be viewed as a substitute to obtaining proper legal or other professional advice, or for reading the policy documents. You should read the policy documents to determine whether any of the insurance product(s) discussed are right for you or your business, noting different limits, exclusions, terms and conditions apply in each country or territory, and not all cover is available in all countries or territories.